ESMO 2023 | The significance of using real-world clinical and genomic data to characterize gliomas

Oriol Mirallas, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses the importance of using real-world clinical and genomic data from next-generation sequencing (NGS) of gliomas to characterize them, elaborating on how they will lead to increased understanding of drug efficacy in the real-world outside of clinical trials. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.